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Background: Little is known about the effect of a splenic rupture on the quality of life (QOL) of patients, although the spleen
is one of the most frequently injured organs in blunt abdominal trauma. It is essential to obtain more knowledge about QOL after
traumatic spleen injury so that this can be taken into account when choosing treatment.
Objective: The primary objective of the SPLENic Injury and Quality of life (SPLENIQ) study is to determine QOL after
treatment for traumatic spleen injury. The secondary objective is to investigate clinical and imaging outcome in relation to QOL.
Methods: A combination of a retrospective single-center and a prospective multicenter observational cohort study will be
conducted. Patients in the retrospective study have had a splenic injury after blunt abdominal trauma and were admitted for
treatment to the ETZ Hospital (Elisabeth-TweeSteden Ziekenhuis) in Tilburg between January 2005 and February 2017. Concerning
the prospective cohort study, patients with splenic injury admitted to 1 of the 10 participating hospitals between March 2017 and
December 2018 will be asked to participate. The follow-up period will be 1 year regarding QOL, clinical symptoms, and imaging.
Patients in the retrospective study will complete 2 questionnaires: World Health Organization QOL assessment instrument-Bref
(WHOQOL-Bref) and 12-Item Short-Form Health Survey (SF-12). Patients in the prospective study will complete 5 questionnaires
at 1 week, 1 month, 3 months, 6 months, and 12 months after treatment: WHOQOL-Bref, SF-12, Euroqol 5-Dimensional 5-Level
(EQ-5D-5L) questionnaire, Institute for Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ), and
iMTA Medical Consumption Questionnaire (iMCQ). In both the retrospective and prospective study, patients treated with splenic
artery embolization will undergo magnetic resonance imaging (MRI). The retrospective group will undergo MRI once, and the
prospective group will undergo MRI 1 month and 1 year after treatment. Treatment of splenic injury depends on the severity of
the splenic injury, the hemodynamic condition of the patient, and the hospital’s or doctor’s preference. This study is observational
in nature without randomization. Concerning the retrospective data, multivariate analysis of covariance will be done. With regard
to the prospective data, mixed linear modeling will be performed.
Results: This project was funded in April 2015 by ZonMw. The results of the retrospective study will be expected in March
2019. With regard to the prospective study, inclusion of patients was completed in December 2018 and data collection will be
completed in December 2019. The first results will be expected in 2019.
Conclusions: To our knowledge, this is the first study that examines QOL in patients with a traumatic spleen injury. The
SPLENIQ study responds to the shortage of information about QOL after treatment for traumatic spleen injury and may result
in the development of a patient-oriented protocol.
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Morbidity and mortality are the most commonly used outcome
parameters in trauma care literature. However, most patients
survive their trauma, and depending on the severity of the
trauma, they will be limited in daily life, both physically and
mentally. Although quality of life (QOL) is recognized as an
important outcome measure, it is still a highly neglected aspect
in trauma care studies, including studies with splenic injury
patients. Multiple studies that did measure QOL have shown
that severely injured patients suffer from psychological
complaints and decreased QOL [1-3]. These factors have a
major social and economic impact because trauma often involves
young patients who frequently are unable to return to work, to
reintegrate back into society, or to retrieve their previous activity
level [4-11]. In case of splenic injury, treatment choices have
to be made in which it is currently unknown what the effects
for these patients will be in the short, medium, and long term.
When more knowledge becomes available about QOL, it will
be useful to determine the choice of treatment.
In blunt abdominal trauma, where the spleen is one of the most
frequently injured organs, much is known about morbidity and
mortality [12]. Internal bleeding caused by abdominal organ
injury is one of the main causes of death after trauma, and a
missed splenic rupture is the most common cause of preventable
death in trauma patients [13,14]. Presently, the standard of care
in hemodynamically stable patients is nonoperative management
(NOM), involving close observation of the patient, with success
rates up to 90% [12]. A recent study among adults with blunt
splenic injury suggests that there are prognostic factors for
failure of NOM. Strong evidence exists for prognostic patient
factors such as age of 40 years or above, Injury Severity Score
of at least 25, and American Association for the Surgery of
Trauma splenic injury grade of 3 or higher [15]. Failure of
therapy leads to more interventions, longer hospital stay, and
higher mortality rates, resulting in increased costs and
presumably decreased QOL. When NOM fails, angiography
and splenic artery embolization (SAE) can be used as a
supplement to NOM. The success rate of SAE ranges between
73% and 100%, with an overall success rate of NOM combined
with SAE ranging between 86% and 100% (most studies
reporting success rates greater than 90%) [16]. Despite this
success rate, much remains unknown about splenic function
after SAE, although it is speculated that there is a relationship
between splenic volume and the immunologic status of the
patient [17-20]. Preservation of splenic function might be one
of the biggest advantages of NOM and SAE. However, patients
treated with SAE have a risk of developing splenic infarction,
abscesses, or cysts, with distal embolization having a
significantly higher association with major complications
compared with proximal embolization [21,22]. Surgery is
indicated when a patient is hemodynamically unstable and does
not respond to transfusion or when associated intraabdominal
injuries require surgical management. Possible disadvantages
of surgery are postsplenectomy complications, such as sepsis,
thrombocytosis, and a lifetime risk of invasive infections
(overwhelming postsplenectomy infection) [23,24]. All
complications may have a major impact on patients’ QOL.
Cost-effectiveness is important in the choice of treatment.
Published study results on hemodynamically stable patients
with splenic injury favored nonsurgical management over
surgery with better clinical and cost results. SAE as a
supplement to NOM trended toward being more cost-effective
with a shorter hospital stay, despite comparable failure rates.
Procedure-related costs were higher for surgery than for SAE,
but total hospital costs were not significantly different [25].
Objectives
There is a growing demand for a (national) guideline or protocol
for clinical decision making in traumatic spleen injury.
Therefore, it is important to determine the optimal selection
criteria for the appropriate management strategy. To achieve
this, the entire process surrounding a patient with splenic injury
must be considered. Even today, it remains unclear what the
impact of QOL is on the entire process. Therefore, the primary
objective of this project is to examine the QOL of patients after
therapy (NOM, SAE, and surgery) for traumatic spleen injury
using a retrospective and prospective group of patients. The
secondary objective is to investigate the clinical outcome (eg,
complications, reinterventions, and additional therapy), imaging
outcome (diagnosis and magnetic resonance spleen imaging
after SAE), and cost outcome (cost-effectiveness) and their
relation to QOL.
Finally, the data and results acquired from this study may result
in the development of a patient-oriented protocol for the
management of traumatic spleen injury.
Methods
Study Design
A combination of a retrospective single-center and a prospective
multicenter observational cohort study will be conducted,
assessing the effects of NOM, SAE, and splenectomy in patients
with splenic injury after blunt abdominal trauma.
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Participants and Centers of Recruitment
Retrospective Study
The study population comprises patients who had a splenic
injury after blunt abdominal trauma and were admitted for
treatment in the ETZ Hospital (Elisabeth-TweeSteden
Ziekenhuis) in Tilburg, the Netherlands, between January 2005
and February 2017. It concerns both men and women who were
18 years or older at the time of screening (February 2017).
Prospective Study
The prospective study will be performed in 10 selected Dutch
hospitals containing experienced interventional radiologists and
trauma surgeons qualified to perform SAE and splenectomy,
respectively. The group includes 7 level-1 trauma centers
(Erasmus MC, ETZ Hospital, Leiden University Medical Center,
Amsterdam University Medical Center, Radboud University
Medical Center, Hospital Medisch Spectrum Twente, and Isala
Hospital) and 3 level-2 trauma centers (Maasstad Hospital
Rotterdam, Albert Schweitzer Hospital Dordrecht, and Amphia
Hospital Breda). The study will be organized in a network
infrastructure in which radiologists and trauma surgeons
collaborate.
All patients with a splenic injury after abdominal trauma
confirmed by ultrasound/focused assessment with sonography
in trauma (US/FAST) and/or computed tomography (CT) at the
primary trauma screening at the 10 participating hospitals
between March 2017 and December 2018 will be asked to
participate.
Inclusion and Exclusion Criteria
Retrospective Study
The inclusion criteria are patients (1) diagnosed with splenic
injury after trauma; (2) who underwent NOM, SAE, or surgery
at the ETZ Hospital; (3) diagnosed between January 2005 and
February 2017; and (4) who were aged 18 years or older at the
time of screening (February 2017). Patients will be excluded
from questionnaires in case of (1) insufficient knowledge of the
Dutch language (verbal and writing) or (2) obviously, death.
Patients treated with SAE will be excluded for magnetic
resonance imaging (MRI) when they do not want to or are not
able to undergo an MRI abdomen (eg, pregnancy or other
contraindications).
Prospective Study
To be eligible to participate, patients (1) must be aged 18 years
or older, (2) have splenic injury after abdominal trauma
(confirmed by US/FAST and/or CT), and (3) must be treated
in 1 of the 10 participating hospitals between March 2017 and
December 2018. Exclusion criteria are identical to those of the
retrospective study.
Sample Size Calculation
As the World Health Organization QOL assessment
instrument-Bref (WHOQOL-Bref) comprises multiple facets,
the retrospective data will be analyzed using a multivariate
analysis of covariance (MANCOVA). This technique is more
powerful than a univariate analysis of variance, resulting in a
required sample size of 135 patients giving a medium effect
and power of 0.80. Previous research [26] indicates that the
minimal clinically important difference (MCID) of the
WHOQOL-Bref slightly varies across its domains. Table 1
shows for each domain the MCID and standard deviation. On
the basis of these statistics, the Cohen d effect sizes were
calculated and transformed via Cohen f to the f2 effect sizes
required in the MANCOVA power analysis. It turns out that
138 participants are required to detect the average f2 of 0.061
with a power of 0.80, given a significance level of .05.
With regard to the prospective data, mixed linear modeling will
be used. Power analysis is performed for a repeated measures
design investigating the interaction between treatment and time.
We assumed a significance level of .05 and a medium effect
size of partial eta squared of 0.05 and an average correlation of
0.50 among the 5 repeated measurements. On the basis of this,
we require 33 participants to test with a power of 0.80, whether
the 3 treatment groups differ in their change in QOL over the
follow-up time. When assuming an effect size similar to the
MCID’s reported in the table above, 27 participants are required
to detect the medium effect of f=0.248 with a power of 0.80.
Study Procedures
Retrospective Study
The clinical and imaging data of all splenic injury patients will
be collected from the electronic patient files and registered
anonymously. To measure QOL, all patients who are still alive
will receive a written letter explaining the study, an informed
consent form, the questionnaires, and a prestamped return
envelope by mail. When a patient is willing to participate, he/she
will sign the consent form and send it back in the return
envelope, together with the completed questionnaires, assessing
QOL and health status. When patients do not complete or return
the questionnaires within 2 weeks, they receive a phone call as
a reminder. When patients do not want to participate, the reason
will be noted if the patient wants to let it be known. The patients
who underwent SAE will be called for a voluntary single MRI
abdomen at the ETZ Hospital in Tilburg.
This study has been reviewed and approved by the Medical
Ethical Committee Brabant (METC Brabant, protocol number:
NL54339.028.15) on January 27, 2016. The study has also been
approved by the local ethical committee of the ETZ Hospital
on February 9, 2016.
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Table 1. Minimal clinically important difference (MCID) per WHOQOL-Bref domain.








In each participating hospital, an interventional radiologist and
a trauma surgeon will be designated as principal investigators.
Each hospital will also have a research assistant, most likely a
radiology technologist or a member of the research team. The
daily work will be carried out by the research assistant under
the supervision of the principal investigator at the ETZ Hospital
(CR). The research assistant will check daily whether potential
eligible patients were admitted to the hospital. This will be done
by checking the subscription list, verbally checking with the
attending (resident) radiologist and trauma surgeon, and
verifying the data in the electronic patient record. The
subscription list will be placed at the dictation station of the
radiologist, where the trauma diagnoses are reported. If a patient
is treated for a traumatic spleen injury, baseline characteristics
will be collected and he/she will be screened for the inclusion
and exclusion criteria. The clinical data of all eligible patients
will be collected anonymously in the database. As soon as the
patient can talk and is lucid, the assistant will visit the patient
to provide a verbal and written explanation about the study. The
time for consideration of participation is 1 week. When a patient
is willing to participate, he/she will sign a consent form. If not,
the reason will be noted if the patient wants to let it be known.
Each inclusion will be reported to the principal investigator
(CR). Total follow-up time is 1 year after treatment with time
points at 1 week and 1, 3, 6, and 12 months after treatment.
Patients will complete the questionnaires at all time points. The
questionnaires of time point 1 will most likely be handed out
to the patients at the hospital ward (intensive care, medium care,
or general ward), usually by the research assistant of that
hospital. At the other time points, patients will be sent an email
to complete the questionnaires, assessing QOL, quality of care,
health care consumption, and return back to work (if applicable).
These questionnaires will be completed by the patient using a
secure Web-based program: Data Management by Research
Manager [27]. If a patient does not have internet, the
questionnaires will be provided on paper with a prestamped
return envelope. When patients do not complete or return the
questionnaires within 2 weeks, they will receive a phone call
as reminder. When patients no longer want to participate, the
reason will be noted if they want to let it be known. Patients
treated with SAE will receive an MRI abdomen 1 month and 1
year after treatment.
This study has been reviewed and approved by METC Brabant
(protocol number: prospective study NL54542.028.16) on May
18, 2016. The study has also been approved by the local ethical
committees of the ETZ Hospital (6-13-2016), Maasstad Hospital
(7-28-2016), Erasmus MC (9-21-2016), Albert Schweitzer
Hospital (10-31-2016), Amphia Hospital (2-23-2017), Leiden
University Medical Center (10-17-2017), Amsterdam University
Medical Center (VUmc) (1-11-2018), Hospital Medisch
Spectrum Twente (1-25-2018), Radboud University Medical
Center (5-3-2018), and Isala Hospital (5-17-2018).
Data Collection
Data of the retrospective and prospective study will be recorded
in a secure online database (Data Management by Research
Manager, Health Solutions Deventer) [27]. In the prospective
study, the database will be available to every research assistant.
The program complies with the new legislation for collecting
and processing personal data in medical scientific research:
General Data Protection Regulation dated May 25, 2018.
Clinical Data
For both the retrospective and prospective study, data will be
collected from the electronic patient records and trauma registry
(Network Emergency Care Brabant). The trauma registry
compiles prehospital and hospital data of all trauma patients
admitted after presentation to the emergency department.
Patients with splenic injury will be identified by the International
Statistical Classification of Disease and Related Health Problems
(ICD-10) and Abbreviated Injury Scale (AIS) diagnosis codes
starting with S36.x and 5442, respectively.
The collected data concern the following: age, sex, systolic
blood pressure, hemoglobin, Glasgow coma scale (at arrival),
intubation (Yes/No), imaging (US and/or CT), grading spleen
injury (American Association for the Surgery of Trauma; see
Table 2)[28], type of treatment (NOM/SAE/splenectomy),
complications, hospital stay (days), spleen in situ at discharge
(Y/N), reinterventions (Y/N), rehospitalization (Y/N), and
mortality.
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Table 2. American Association for the Surgery of Trauma spleen injury scaling (1994 Revision).
Injury descriptionGradea
I
Subcapsular <10% of surface areaHematoma
Capsular tear <1 cm parenchymal depthLaceration
II
Subcapsular 10%-50% of surface area; or intraparenchymal <5 cm in diameterHematoma
1-3 cm parenchymal depth, which does not involve a trabecular vesselLaceration
III
Subcapsular >50% of surface area or expanding; or ruptured subcapsular or parenchymal hematoma; or intraparenchymal hematoma
>5 cm or expanding
Hematoma
>3 cm parenchymal depth or involving trabecular vesselsLaceration
IV
Involving segmental or hilar vessels producing major devascularization (>25% of the spleen)Laceration
V
Completely shattered spleenLaceration
Hilar vascular injury with devascularized spleenVascular
aAdvance one grade for multiple injuries, up to grade III.
Questionnaires
Patients in the retrospective study will complete the
questionnaires once. Patients in the prospective study will
complete questionnaires at 1 week and 1, 3, 6, and 12 months
after treatment (see Table 3).
World Health Organization Quality of Life Assessment
Instrument-Bref
QOL will be assessed with the World Health Organization
Quality of Life Assessment Instrument-Bref (WHOQOL-Bref)
[29]. This 26-item questionnaire is a short version of the
WHOQOL-100, and it assesses 4 domains (physical health,
psychological health, social relationships, and environment) as
well as 1 general facet, Overall QOL and General Health. The
questions in the domains are derived from the 24 facets of the
WHOQOL-100, with 1 item from each of the facets. Each item
is rated on a 5-point rating scale. Higher scores indicate a better
QOL [29,30]. The WHOQOL-Bref has good psychometric
properties [30-33].
12-Item Short-Form Health Survey
The 12-Item Short-Form Health Survey (SF-12) is a shorter
version of the 36-Item Short-Form Health Survey (SF-36), which
will be used for evaluating individual patients’ health status,
researching the cost-effectiveness of a treatment, and monitoring
and comparing disease burden. The SF-12 covers 8 domains:
physical functioning, role limitations because of physical
problems, bodily pain, general health, vitality, social functioning,
role limitations because of emotional problems, and mental
health [34,35]. From these domains, summary scores for the
physical component (PCS) and mental component (MCS) can
be computed. The 12 items for the SF-12 were selected such
that the SF-12 component scores explain 90% of the variability
in PCS and MCS scores of the SF-36 [34]. The SF-36 was used
as a criterion for validation of the SF-12. The SF-12 and the
SF-36 components and scales are scored with the algorithms
specified by the developer [35]. The minimum possible score
is 0 and the maximum possible score is 100. The SF-12 has
good reliability and validity [36-42].
Euroqol 5-Dimensional 5-Level Questionnaire
The Euroqol 5-Dimensional 5-level questionnaire (EQ-5D-5L)
is a generic health status instrument that measures health-related
QOL [43]. The descriptive system of the instrument comprises
5 dimensions (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression), which can be scored
with 5 levels (ranging from no problems to severe problems).
For the purpose of cost-effectiveness studies, health status is
expressed in utilities, with a scale from 0 (death) to 1 (perfect
health). The EQ-5D-5L can be used to derive utilities; the Dutch
tariff can be used for this purpose [44]. Moreover, the EQ-5D-5L
has good psychometric properties [45-50].
iMTA Productivity Cost Questionnaire
The impact of disease on the ability of a person to perform work
should be part of an economic evaluation when a societal
perspective is applied. The iMTA Productivity Cost
Questionnaire (iPCQ) is a generic, nondisease-specific
questionnaire, and it is applied in national and international
studies [51]. The questionnaire is currently available in more
than 10 languages, including Dutch. Both indirect cost because
of absenteeism and the productivity losses because of
presenteeism (ie, sick, but working) are taken into account. A
manual is available, containing information on the modular
structure of the iPCQ and its scoring and valuation methods that
are used for cost calculations. By applying productivity costs,
the answers of the iPCQ can be monetized and, as such, used
in health economic evaluations.
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Table 3. Timeline of the prospective study concerning measurements.
ImagingQuestionnairesDemographicsTiming and settingTime point
—eQuality of life (WHOQOL-Brefa); health




After treatment, during ad-
mission
T1
MRI (SAEj patients only)Quality of life (WHOQOL-Bref); health
status (SF-12); health-related QOL (EQ-5D-
5L); productivity costs (iPCQh); and medi-
cal consumption (iMCQi)




—eQuality of life (WHOQOL-Bref); health
status (SF-12); health-related QOL (EQ-5D-
5L); productivity costs (iPCQ); and medical
consumption (iMCQ)
—g3 months after treatment, at
home
T3
—eQuality of life (WHOQOL-Bref); health
status (SF-12); health-related QOL (EQ-5D-
5L); productivity costs (iPCQ); and medical
consumption (iMCQ)
—g6 months after treatment, at
home
T4
MRI (SAE patients only)Quality of life (WHOQOL-Bref); health
status (SF-12); health-related QOL (EQ-5D-
5L); productivity costs (iPCQ); and medical
consumption (iMCQ)
Clinical data1 year after treatment, at
home (MRI: outpatient clin-
ic)
T5
aWHOQOL-Bref: World Health Organization Quality of Life assessment instrument-Bref.
bSF-12: 12-Item Short-Form Health Survey.
cQOL: quality of life.
dEQ-5D-5L: Euroqol 5-Dimensional 5-Level questionnaire.
eAt this time point, no MRIs have been completed.
fMRI: magnetic resonance imaging.
gAt this time point, no demographic or clinical data have been collected.
hiPCQ: iMTA Productivity Cost Questionnaire.
iiMCQ: iMTA Medical Consumption Questionnaire.
jSAE: splenic artery embolization.
iMTA Medical Consumption Questionnaire
The iMTA Medical Consumption Questionnaire (iMCQ) is a
generic, nondisease-specific instrument for measuring (direct)
medical costs [52]. The instrument is a standardized
self-reported questionnaire. The iMCQ includes questions
related to frequently occurring contacts with health care
providers and can be complemented with extra questions that
are relevant for specific study populations. A manual is available
for a structured use of the questionnaire. For the valuation of
resource use, as obtained from the iMCQ, reference unit prices
can be used. These reference prices can be derived from the
Dutch manual for costing studies. The manual was
commissioned and published by Zorginstituut Nederland and
authored by the Institute for Medical Technology Assessment
(iMTA) [53].
MRI Abdomen After Splenic Artery Embolization
Patients in the retrospective study will undergo MRI once at
the ETZ Hospital in Tilburg, and patients in the prospective
study will undergo MRI 1 month and 1 year after treatment at
the hospital where the treatment took place. Not all hospitals
have the same MRI scanner. However, the same scan protocol
will be used at all locations, leading to comparable images and
assessments (see Table 4).
Only patients treated with SAE will receive an MRI of the upper
abdomen to evaluate the spleen morphologically (volume,
necrosis, splenosis, calcifications, and chronic infarction) and
dynamically (diffusion and enhancement).
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Table 4. Magnetic resonance imaging scan protocol.
Prospective studyRetrospective study
Axial Dual FFE/GRE (in-out phase); Coronal T2-weighted TSE/FSE;
Axial T2-weighted TSE/FSE; Axial BFFE/BGRE Volume (5 mm slices,
no gap); Axial DWI with b value=0/400/800
Axial Dual FFEa/GREb (in-out phase); Coronal T2-weighted TSEc/FSEd;
Axial T2-weighted TSE/FSE; Axial BFFEe/BGREf Volume (5 mm slices,
no gap); Axial DWIg with b value=0/400/800
Axial dynamic T1-weighted noncontrast with fat sat; Axial T1-weighted
3D magnetic resonance angiography contrast-enhanced; Axial dynamic
T1-weighted contrast-enhanced (2 time points) with fat sat
3Dh (noncontrast)
aFFE: Fast Field Echo.
aGRE: Gradient Echo.
cTSE: Turbo Spin Echo.
dFSE: Fast Spin Echo.
eBFFE: Balanced Fast Field Echo.
fBGRE: Balanced Gradient Echo.
gDWI: Diffusion Weighted Images.
h3D: three-dimensional.
Statistical Analysis
All analyses will be conducted using SPSS V24.0 (Statistical
Package for Social Sciences, Chicago Illinois, USA).
Frequencies and descriptive statistics will be calculated to
provide an overview of the characteristics of the study
population. Statistical test results will be considered significant
at a level of P<.05.
Concerning the retrospective study, a MANCOVA will be done
after correcting theoretically important covariates to assess the
differences between treatment groups on the 4 WHOQOL-Bref
domains and the general facet. For each type of treatment, a 1
sample t test will be performed for each WHOQOL-Bref scale
to compare the QOL scores with reference data.
For both the retrospective and prospective studies, a logistic
regression analysis will be performed on the outcome variables’
(1) need for reintervention (yes/no) and (2) for each
complication (yes/no), assessing the effect of treatment after
correcting for theoretically important covariates. With regard
to hospital stay in days, a Kruskal-Wallis test will be performed
with the group (type of treatment) and days in hospital. Analysis
of covariance will be used to compare proximal versus distal
SAE, thereby correcting the effect for theoretically important
covariates. To confirm/find prognostic factors for failure of
NOM, a logistic regression analysis will be performed if NOM
is a failure quickly after treatment. Otherwise, a survival analysis
will be performed.
Regarding the prospective study, to assess the differences
between groups in their change in QOL over time, a linear mixed
model analysis will be conducted. To answer our research
question, we will focus on the interaction effect between
measurement occasion and treatment group, while correcting
for theoretically important covariates. For the repeated measures,
an unstructured covariance matrix will be used. Item-level
missing values will be imputed according to the guidelines of
the questionnaires. Scale-level missing values will be handled
directly through maximum likelihood estimation, because the
mixed model procedure makes use of all available data for each
participant over all time points.
To conduct the cost-effectiveness analysis, a cost-effectiveness
model will be developed. This model will comprise 2 treatment
arms; SAE will be compared with splenectomy. The
cost-effectiveness study will be conducted according to the most
recent Dutch guidelines for health economic research [54]. As
such, the study will be performed from the societal perspective,
which means that all costs and benefits should be considered,
regardless of by whom the costs are borne or to whom the
benefits accrue.
Effects will be expressed in quality-adjusted life years, which
constitute a combination of QOL and length of life. QOL will
be measured in utilities. Utilities express QOL on a scale from
0 (death) to 1 (perfect health). Utilities can be derived from the
EQ-5D-5L [44]. Survival will be derived from international
clinical literature. Costs will be estimated according to the Dutch
Manual for Costing in Economic Evaluations, update 2015,
using a societal perspective [54]. A bottom-up methodology
will be used to compute costs; the total number of medical
contacts will be multiplied with unit costs. Direct medical costs
comprise all costs directly relating to the prevention, diagnostics,
therapy, rehabilitation, and care of the intervention. Health care
utilization will be derived from the iMCQ [52]. The iPCQ will
be used to assess productivity losses [51]. The friction cost
method will be used for the calculation of costs because of
production losses [55]. This method is the expertise of the
iMTA; it is its standard method and has been widely used.
Regulation Statement
The study will be conducted according to the principles of the
Declaration of Helsinki (7th revision, 64th World Medical
Association General Assembly, Fortaleza, Brazil, October 2013)
and in accordance with the Medical Research Involving Human
Subjects Act (WMO).
Results
For the retrospective study, the data collection has taken place
and the database is complete. Results will be reported in March
2019. Enrollment of participants in the prospective study began
in March 2017, and it was completed in December 2018. Data
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collection will be completed in December 2019. The first results
will be reported in 2019.
Discussion
The SPLENic Injury and Quality of life (SPLENIQ) study is
the first study that examines the effect of traumatic spleen injury
on patients’ QOL in both a retrospective and prospective
observational study design. It also examines clinical and imaging
outcome as well as cost-effectiveness. For several reasons, these
studies add relevant information to the existing literature. First,
there is a need for research into QOL after traumatic spleen
injury, because this is an important but neglected factor in the
trauma care literature. If more knowledge becomes available,
this can be taken into account when choosing treatment. Second,
the prospective study will be conducted in a multicenter context
in 10 hospitals, involving a trauma surgeon and interventional
radiologist in each hospital. This creates a strong collaboration
between the participating hospitals and medical specialties,
which hopefully adds to the inclusion rate. Third, it is still
unknown what impact different SAE techniques and materials
have on the morphology and volume of the spleen. To
investigate this, using MRI is innovative and will provide
interesting images containing important and necessary
information.
Several factors related to the design and execution must be taken
into account. First, patients will be treated with NOM, SAE, or
surgery for a specific clinical condition. It may be the clinical
situation that determines the long-term outcome, although that
outcome is not or partially the result of the treatment. This risk
is confounding by indication: the risk that the groups are in fact
not easily comparable (ie, selection bias). To keep this to a
minimum, the reason for choosing a particular treatment will
be registered. In our analysis, we will correct for these
confounding factors using propensity score analysis. Correction
is only possible when adequate and good-quality information
is available about the clinical condition of the patients, which
led to the decision. The patient’s record will be searched
thoroughly to find this information. Second, trauma patients
often have multiple injuries that can affect QOL and clinical
outcomes. We are not primarily interested in these additional
injuries, but these will be included as a covariate in the analysis.
Third, response bias may occur in the questionnaires group.
Patients may decline participation because they are not interested
or it may be too confronting to think/correspond about their
psychological state. Fourth, the severely injured patients may
be overrepresented in the nonresponse group concerning the
questionnaires. To limit this, these patients will be visited as
soon as they are approachable and, if necessary, will be provided
assistance to complete the questionnaires. Fifth, the absence of
randomization is a (strong) limitation and a potential source of
bias, but randomized comparison in managing trauma patients
is virtually impossible. Furthermore, it will have strong ethical
implications as it is well known that randomizing trauma patients
with intraabdominal bleeding, potentially unstable, is something
not feasible in clinical practice. Sixth, the sample size calculation
is based on the primary objective of the study. For the clinical
and cost-effectiveness analysis, this implies that because of the
small sample size, the uncertainty about the outcome is large.
Seventh, we are aware of response shift bias. Response shift is
a change in self-reported QOL that is a result of a change in
internal standards (ie, recalibration), values (ie, reprioritization),
or meaning of QOL (ie, reconceptualization) [56,57]. Thus,
response shift reflects psychological adaptation: we do not
consider this as a problem but as a fact of life. In addition, the
method to prevent response shift contains recall bias itself.
Considering this, and the fact that QOL is a generic outcome
measure, ensures that we use the chosen method. Moreover, the
retrospective patients will not be included in the prospective
study.
In conclusion, the SPLENIQ study responds to the shortage of
information about QOL after treatment for traumatic spleen
injury. With developing a patient-oriented protocol, a necessary
step is taken to customize standard care, which may contribute
to a positive effect on QOL and clinical outcome.
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WHOQOL-Bref: World Health Organization Quality of Life assessment instrument-Bref
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